Close Menu

Arrowhead

The deal gives Arrowhead access to technologies developed by Novartis, a license to Alnylam intellectual property, and a pipeline of three preclinical RNAi drug candidates.

The disease is characterized by the accumulation of a mutant protein in the liver, leading to fibrosis, cirrhosis, and potentially cancer.

The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.

The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.

The studies will test Arrowhead's drug in combination with one of two direct-acting antiviral therapies.

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

Officials said the firm remains confident in its HBV drug despite investors' negative reaction to Phase IIa data.

 

The trial is set to run in Australia.

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

NEW YORK (GenomeWeb) – Just days after presenting Phase II data on its lead hepatitis B drug candidate that failed to meet Wall Street expectations and sent its stock into a tailspin, Arrowhead Research has been sued in two class action lawsuits alleging that the company misled investors as to wh

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.